Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jan;42(1):138-143.
doi: 10.3174/ajnr.A6832. Epub 2020 Sep 17.

COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke

Affiliations
Multicenter Study

COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke

J Siddiqui et al. AJNR Am J Neuroradiol. 2021 Jan.

Abstract

Background and purpose: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker.

Materials and methods: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate statistics.

Results: Apical ground-glass opacification was present in 22.2% (50/225) of patients. Ground-glass opacification had high interrater reliability (Fleiss κ = 0.81; 95% CI, 0.68-0.95) and, compared with reverse-transcriptase polymerase chain reaction, had good diagnostic performance (sensitivity, 75% [95% CI, 56-87]; specificity, 81% [95% CI, 71-88]; OR = 11.65 [95% CI, 4.14-32.78]; P < .001) on multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .017; hazard ratio = 3.51; 95% CI, 1.42-8.66; P = .006).

Conclusions: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
A, There are multiple, bilateral, focal, peripheral-predominant areas of ground-glass opacification, commonly seen in patients with COVID-19 pulmonary infection. B, There are multiple, focal 5- to 6-mm nodules with surrounding ground-glass change in the left upper lobe. This is an indeterminate COVID-19 appearance and would be more suggestive of atypical or fungal infection. C, There is bilateral ground-glass opacification posteriorly, more on the right, consistent with dependent change. This is a characteristic appearance, not associated with COVID-19, and classically disappears in the prone position. There is also a general hazy appearance not seen in A and B, which does not represent abnormal lung and is artifactual due to movement.
FIG 2.
FIG 2.
Kaplan-Meier analysis. Association between GGO and mortality was evaluated using Kaplan-Meier survival analysis; 82.0% of patients in the group with GGO were alive at 30 days compared with 94.3% in the group without GGO (P = .005).

Comment in

References

    1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica.... Accessed June 20, 2020
    1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO Director-General's opening remarks at the media briefing on COVID-19.... Accessed June 20, 2020
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020. March 13 [Epub ahead of print] 10.1001/jama.2020.4031 - DOI - PubMed
    1. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395:1225–28 10.1016/S0140-6736(20)30627-9 - DOI - PMC - PubMed

Publication types